SYMPA
25.8.2020 09:02:06 CEST | Business Wire | Pressemeddelelse
HR-teknologiselskabet Sympa offentliggjorde i dag, at de har godkendt en majoritetsinvestering fra Providence Strategic Growth (“PSG”). PSG er et datterselskab af Providence Equity Partners, en af verdens førende kapitalfonde med fokus på teknologiselskaber. Det nordiske investeringsselskab Alfvén & Didrikson, der investerede i Sympa i 2016, forbliver minoritetsejere sammen med Sympas stiftere. Edward Hughes, Aldo Mareuse og Tobias Richter fra PSG sidder nu i Sympas bestyrelse. Ingen finansielle detaljer er offentliggjorte.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200825005033/da/
“Vi valgte Sympa som partner, fordi det er et veldrevet og spændende firma med stort potentiale, som er på forkant med udviklingen af europæiske HR-systemer” siger Edward Hughes, CEO hos PSG. “Markedet vokser hurtigt, og virksomheder efterspørger nu avancerede digitale HR-værktøjer, hvilket skaber interessante vækstmuligheder for Sympa. Vi ser frem til at samarbejde med Keijo og hans team for at nå virksomhedens fulde potentiale og fremskynde den internationale ekspansion.”
Sympa blev grundlagt i 2005 og er i dag en af Nordens førende og hurtigst voksende leverandører af cloud-baserede HR-løsninger. Selskabets mest populære produkt, Sympa HR, er en omfattende HR-løsning for digital håndtering af HR, som giver et tydeligt overblik over medarbejderdata og HR-processer. PSG’s investering vil understøtte Sympas næste vækstfase; produktudvikling og strategisk M&A for at fremme ekspansionen i hele Europe. Medstifter og CEO Keijo Karjalainen fortsætter med at stå i spidsen for både den daglige drift og Sympas team bestående af 140 medarbejdere, fordelt på 8 kontorer i 5 lande.
“Lige siden vi grundlagde Sympa, har vi været overbevist om, at der er et uudforsket behov for HR-systemer, der kan håndtere alle HR-processer og muliggøre datadrevet HR-arbejde. Vi har også identificeret en mangel på HR-systemer til mellemstore virksomheder med aktiviteter i flere forskellige lande og den kompleksitet, det medfører. Ved at imødekomme begge disse behov og samtidig sætte kunden først, har Sympa været i stand til at vokse hurtigt, og med PSG på vores side, mener vi, at der er meget gode vilkår for at få en markedsledende position uden for vores nordiske hjemmemarkeder. Det bliver meget spændende at se, hvad fremtiden har at vise” siger Keijo Karjalainen, medstifter og CEO.
Sympa hjælper i øjeblikket mere end 700 virksomheder verden over med at fremme udviklingen af deres medarbejdere, strømline HR-processerne og træffe endnu smartere strategiske beslutninger. Sympas kunder inkluderer flere kendte brands som Dustin, LandboNord, WhiteAway, VMS Group og Napatech. Sympa har tidligere toppet IT-magasinet Red Heerings liste med de 100 mest lovende start-ups.
Om Sympa
Sympa HR er en komplet HR-løsning, der nemt kan tilpasses, så den matcher virksomheden perfekt, og brugerne kan fokuserer på medarbejderne og smart beslutningstagning. HR-løsningen giver et tydeligt og samlet overblik over alle medarbejderdata, hjælper med at automatisere en lang række af de daglige HR-opgaver og samler alle HR-data et sikkert sted. Sympa HR anvendes nu gennemsnitligt 650.000 gange hver måned i 700+ virksomheder i mere end 100 lande. I 2019 vandt Sympa ”Året HR-systemprojekt ”, og har en de højeste kundetilfredshedsrater inden for HR-teknologi i Europa. Læs mere om Sympa HR-løsningen og selskabet kunder på sympa.dk .
Om Providence Strategic Growth
PSG, et datterselskab af Providence Equity Partners (“Providence”), blev etableret i 2014 og fokuserer på kapitalinvesteringer i teknologiselskaber med stærk vækst. Providence er et førende kapitalforvaltningsselskab, der har en sektorfokuseret investeringsstrategi. Siden selskabets start i 1989 har Providence investeret i mere end 200 virksomheder og er en af de førende kapitalfonde med fokus på medier, kommunikation, uddannelse, software og serviceindustrien. Providence har tidligere investeret i TDC. Selskabet har hovedsæde i Boston, USA, og kontorer i London og Kansas City. Læs mere på https://www.provequity.com .
Om Alfvén & Didrikson
Det svenske investeringsselskab Alfvén & Didrikson er et veletableret selskab, som specialiserer sig i passionerede start-ups med internationale vækstambitioner. Siden 2010 har Alfvén & Didrikson investeret i hurtigt voksende nordeuropæiske virksomheder, som eksempelvis Quinyx, Trustly, Mentimeter, Acast, Offerta og PE Accounting. Læs mere på www.alfvendidrikson.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200825005033/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
